Tandem Diabetes Care Inc (TNDM) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Tandem Diabetes Care reported revenue of $1.01B, up 7.9% from $940.2M the year before. Net income was -$204.7M (a -20.2% net margin), or -$3.04 per diluted share. Gross margin was 53.8% and operating margin was -18.5%. Operating activities generated -$9.7M of cash, leaving -$29.7M of free cash flow. At fiscal year end, Tandem Diabetes Care held $881.1M in total assets against $725.9M in total liabilities, including $90.6M of cash and equivalents.
Open the full interactive Tandem Diabetes Care financials → Quarterly statements, key ratios, valuation history and price charts.
Tandem Diabetes Care Key Stats
| Share Price | $16.65 |
|---|---|
| Market Cap | $1.15B |
| Revenue YoY Growth | +7.9% |
| 52-Week Range | $12.82 – $28.26 |
| Shares Outstanding | 69.0 million (basic, 2026 Q2) |
Tandem Diabetes Care Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $498.8M | $702.8M | $801.2M | $747.7M | $940.2M | $1.01B |
| Cost of Goods Sold | $238.3M | $326.6M | $388.2M | $380.0M | $450.6M | $468.7M |
| Gross Profit | $260.5M | $376.2M | $413.0M | $367.7M | $489.6M | $546.0M |
| Operating Income | -$8.0M | $22.7M | -$92.8M | -$233.2M | -$99.1M | -$187.3M |
| Pre-Tax Income | -$36.3M | $15.9M | -$92.9M | -$220.3M | -$91.9M | -$200.3M |
| Income Tax | -$1.9M | $335,000 | $1.7M | $2.4M | $4.2M | $4.4M |
| Net Income | -$34.4M | $15.6M | -$94.6M | -$222.6M | -$96.0M | -$204.7M |
| Diluted EPS | $0.22 | $0.24 | -$1.47 | -$3.43 | -$1.47 | -$3.04 |
Tandem Diabetes Care Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $249.3M | $290.4M | $247.2M | $254.6M |
| Net Income | -$21.2M | -$589,000 | -$20.4M | -$21.2M |
| Diluted EPS | -$0.31 | -$0.01 | -$0.30 | -$0.31 |
Tandem Diabetes Care Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $94.6M | $71.2M | $172.5M | $58.9M | $69.2M | $90.6M |
| Current Assets | $637.2M | $811.5M | $850.0M | $748.0M | $724.5M | $618.1M |
| Total Assets | $716.4M | $905.1M | $1.05B | $952.7M | $967.7M | $881.1M |
| Current Liabilities | $103.9M | $131.9M | $165.3M | $195.3M | $247.0M | $242.7M |
| Total Long-Term Debt | $203.0M | $281.5M | $283.2M | $285.0M | $348.9M | $310.0M |
| Total Liabilities | $350.1M | $472.0M | $612.8M | $639.0M | $704.6M | $725.9M |
| Shareholders' Equity | $366.3M | $433.1M | $439.9M | $313.6M | $263.1M | $155.2M |
Tandem Diabetes Care Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $24.7M | $111.4M | $50.5M | -$31.8M | $24.2M | -$9.7M |
| Cash From Investing | -$296.1M | -$186.9M | $33.2M | -$85.7M | -$23.5M | $72.9M |
| Cash From Financing | $314.4M | $51.9M | $16.9M | $4.1M | $8.4M | -$43.4M |
| Free Cash Flow | -$2.7M | $97.2M | $16.4M | -$58.6M | $5.0M | -$29.7M |
Figures from Tandem Diabetes Care's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tandem Diabetes Care financials page for every line item.
Tandem Diabetes Care Company Profile
| Ticker | TNDM |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001438133 |
Frequently Asked Questions
What was Tandem Diabetes Care's revenue in fiscal 2025?
Tandem Diabetes Care (TNDM) reported revenue of $1.01B for fiscal 2025.
What is Tandem Diabetes Care's annual revenue history?
Tandem Diabetes Care's annual revenue by fiscal year: 2020: $498.8M; 2021: $702.8M; 2022: $801.2M; 2023: $747.7M; 2024: $940.2M; 2025: $1.01B.
What was Tandem Diabetes Care's net income in fiscal 2025?
Tandem Diabetes Care reported net income of -$204.7M for fiscal 2025.
What was Tandem Diabetes Care's earnings per share (EPS) in fiscal 2025?
Tandem Diabetes Care's diluted EPS was -$3.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tandem Diabetes Care generate in fiscal 2025?
Tandem Diabetes Care generated -$29.7M of free cash flow in fiscal 2025.
What was Tandem Diabetes Care's revenue last quarter?
In its most recent reported quarter (2026 Q2), Tandem Diabetes Care reported revenue of $254.6M.
How much debt does Tandem Diabetes Care have?
Tandem Diabetes Care reported $310.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Tandem Diabetes Care are outstanding?
Tandem Diabetes Care reported a weighted average of 69.0 million basic shares outstanding in 2026 Q2.
What is Tandem Diabetes Care's market cap?
Based on its latest closing price, Tandem Diabetes Care (TNDM) has a market capitalization of about $1.15B.
When does Tandem Diabetes Care's fiscal year end?
Tandem Diabetes Care's fiscal year end, as registered with the SEC, is December 31.
Where is Tandem Diabetes Care headquartered?
Tandem Diabetes Care lists its business address in San Diego, California in its SEC filings.
Tandem Diabetes Care Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →